Stock BIOC GLAXOSMITHKLINE S.A.E
Add to a list
To use this feature you must be a member
Log inSign up

GlaxoSmithKline S.A.E Share Price

Equities

BIOC

EGS38171C012

Pharmaceuticals

End-of-day quote Egyptian Exchange
Other stock markets
 03:30:00 24/04/2024 am IST 		5-day change 1st Jan Change
32.32 EGP +2.41% Intraday chart for GlaxoSmithKline S.A.E -0.15% -9.09%
04/03 GlaxoSmithKline S.A.E Reports Earnings Results for the Full Year Ended December 31, 2023 CI
2023 GlaxoSmithKline S.A.E Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI

Financials

Sales 2022 1.82B 38.1M 3.18B Sales 2023 2.24B 46.82M 3.9B Capitalization 2.97B 62.05M 5.17B
Net income 2022 718M 15.01M 1.25B Net income 2023 74M 1.55M 129M EV / Sales 2022 1.47 x
Net cash position 2022 511M 10.67M 890M Net cash position 2023 728M 15.22M 1.27B EV / Sales 2023 1 x
P/E ratio 2022
4.44 x
P/E ratio 2023
40.1 x
Employees -
Yield 2022
1.97%
Yield 2023
-
Free-Float 2.91%
More Fundamentals * Assessed data

Chart GlaxoSmithKline S.A.E

Dynamic Chart

Latest news about GlaxoSmithKline S.A.E

GlaxoSmithKline S.A.E Reports Earnings Results for the Full Year Ended December 31, 2023 CI
GlaxoSmithKline S.A.E Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
GlaxoSmithKline S.A.E Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
GlaxoSmithKline S.A.E Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
GlaxoSmithKline S.A.E Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
GlaxoSmithKline S.A.E Reports Earnings Results for the Full Year Ended December 31, 2021 CI
GlaxoSmithKline S.A.E Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021 CI
GlaxoSmithKline S.A.E Reports Consolidated Earnings Results for the Six Months Ended June 30, 2021 CI
Glaxosmithkline S.A.E Reports Standalone and Consolidated Financial Results for the Quarter Ended March 31, 2021 CI
Glaxosmithkline S.A.E Announces Audited Consolidated Earnings Results for the Year Ended December 31, 2020 CI
Hikma Pharmaceuticals PLC cancelled the acquisition of GlaxoSmithKline S.A.E. CI
Glaxo Group Receives Letter from ACDIMA for Acquisition of Glaxosmithkline Shares CI
Hikma Pharmaceuticals PLC entered into a non-binding term sheet to acquire 91.2% stake in GlaxoSmithKline S.A.E from Glaxo Group Limited. CI
GlaxoSmithKline S.A.E Reports Audited Standalone Earnings Results for the Year Ended December 31, 2019 CI
GSK Egypt to Launch 2 Production Lines with EGP 100 million Investments CI
More news

Press releases GlaxoSmithKline S.A.E

GlaxoSmithKline E : Glaxo Smith Kline (BIOC.CA) - Listing Committee Decision PU
GSK hires former Tesco boss Sir Dave Lewis to head up £40bn spin-off AQ
More press releases

Quotes and Performance

1 day+2.41%
1 week-0.15%
Current month+7.63%
1 month+3.23%
3 months-13.19%
6 months-1.10%
Current year-9.09%
More quotes

Highs and lows

1 week
30.31
Extreme 30.31
33.94
1 month
29.00
Extreme 29
36.00
Current year
28.20
Extreme 28.2
47.50
1 year
26.26
Extreme 26.26
47.50
3 years
16.66
Extreme 16.66
47.50
5 years
5.77
Extreme 5.77
47.50
10 years
0.00
Extreme 0
47.50
More quotes

Managers and Directors - GlaxoSmithKline S.A.E

Managers TitleAgeSince
Ashraf Mohammed Ibrahim Mansour CHM
 Chairman - -
Ahmed Ramadhan Rashad IRC
 Investor Relations Contact - -
Members of the board TitleAgeSince
Sherine El-Ansari BRD
 Director/Board Member - -
Ashraf Mohammed Ibrahim Mansour CHM
 Chairman - -
Munir Ghabour Hanna BRD
 Director/Board Member - -
More insiders

Quotes

Date Price Change Volume
24/24/24 32.32 +2.41% 28,669
23/24/23 31.56 -0.03% 17,776
22/24/22 31.57 -3.01% 30,319
21/24/21 32.55 +0.56% 26,179

End-of-day quote Egyptian Exchange, April 24, 2024

More quotes

Company Profile

GlaxoSmithKline Egypt S.A.E. specializes in the development, manufacture and marketing of medicines. Their products are for the treatment of diabetes, asthma, cancer, hepatic viruses, infections, allergies and gastro-intestinal and cardiovascular diseases.
Sector
Pharmaceuticals
More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

1st Jan change Capi.
GLAXOSMITHKLINE S.A.E Stock GlaxoSmithKline S.A.E
-9.09% 56.35M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
NOVARTIS AG Stock Novartis AG
+5.46% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. BIOC Stock